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Introduction
Albumin is the most ubiquitous plasma protein in human serum and is a nonspecific protein transport for numerous hormones including aldosterone, thyroid hormones (T3 and T4), and androgens (Rothschild, 1988; Sherwood, 1997) . Serum albumin is an acute phase reactant (Rothschild, 1988) . Its levels in circulation are reduced from inflammatory cytokines such as tumor necrosis factor (TNF) -a, C-reactive protein, and particularly interleukin (IL)-6 (Johnson, 1999; Gabay & Kushner, 1999; Sullivan et al., 2007) . Serum albumin levels can be reduced substantially following major surgery or sepsis (Emerson, 1989 ) and more modest reductions have been observed from subclinical inflammation (Sullivan et al., 2007) . Low serum albumin is associated with an increased risk of cardiovascular disease (Weijenberg et al., 1997; Gillum & Makuc, 1992; Kaysen, 2006) , disability (Zuliani et al., 2001) , and mortality (Gillum & Makuc, 1992; Fried et al., 1998; Weijenberg et al., 1997) .
Sarcopenia is a term used to describe the progressive decline of skeletal muscle mass and I -------muscle-function with age. These-muscle changes are highly-prevalent-in-the-elderly-population-------and have been estimated to affect 13-24% of persons under age 70 and greater than 50% in persons over 80 years of age (Baumgartner et al., 1998; Castillo et al., 2003; 1annuzzi.-Sucich, 2002 ). Loss of muscle mass and muscle function have been associated with a number of deleterious health outcomes including frailty, loss of independence, physical disability (Guralnik et al., 1995; Baumgartner et al., 1998; Morley et al., 2001) , falls (Baumgartner et al., 1998;  I Chan et al., 2007) , and all-cause mortality (Rantanen et al., 2003; Newman et al., 2006) . These age-related changes in muscle are likely to have multiple causes (Roubenoff, 2000) . An imbalance between muscle catabolism and anabolism (Soloman & Bouloux, 2006; Roth et al., 2006; Kaysen, 2006; Roubenoff & Hughes, 2000) , acceleration of myocyte loss through I apoptosis (Marzetti & Leeeuwenburgh, 2006; Soloman & Bouloux, 2006; Roubenoff & Hughes, 2000) , reduction in type II muscle fibers (Karakelides & Nair, 2005; Morley et al., 2001) , inflammation (Roth et al., 2006; Soloman & Bouloux, 2006; Roubenoff & Hughes, 2000) , loss of alpha motor neurons (Roubenoff & Hughes, 2000) , and age-related anorexia and hormonal changes (Soloman & Bouloux, 2006; Morley et al., 2001; Morley, 2001 ) have all been,proposed as potential physiologic mechanisms.
The involvement of serum albumin in relevant hormone pathways and reaction to systemic inflammation make it a viable biologic risk factor for the age-related decline in skeletal muscle mass and muscle function. In support of this hypothesis, two cross-sectional studies have reported an association between low serum albumin and lower measures of muscle strength (Kwon et al., 2007) and muscle mass (Baumgartner et al., 1996) in elderly persons. In addition, I I two longitudinal studies in community-dwelling elderly populations have reported a statistically significant association between low baseline measures of serum albumin and declines in appendicular skeletal muscle mass (Visser et al., 2005) and grip strength (Schalk et al., 2005) .
Nonetheless, the research investigating the role of serum albumin in the progressive decline of I albumin in relation to multiple measures of muscle change in the same study population.
I
Moreover, no studies have examined change in serum albumin concentration with concurrent change in muscle mass and muscle function.
This prospective study quantified the association of baseline serum albumin with change in muscle mass, muscle strength, and muscle power in a large cohort of older ambulatory men. In I addition, the association of serum albumin change with these muscle outcomes was examined 1 in a sample of the cohort for whom the 2 year change in serum albumin concentration could be ascertained.
Methods
Study Setting
The Osteoporotic Fractures in Men (MrOS) Study is a prospective cohort study of 5995 community-dwelling men aged 65 years or older. Men were recruited from March 2000 through April 2002 at six U.S. academic medical centers in Birmingham, Alabama; Minneapolis, Minnesota; Palo Alto, California; Pittsburgh, Pennsylvania; Portland, Oregon; and San Diego, California. Eligible men were at least 65 years of age, able to walk without the assistance of another person, and had at least one native hip. Details regarding the recruitment strategies and study design are described elsewhere (Blank et al., 2005 & Orwoll et al., 2005 . All surviving participants were invited to return for a planned second study visit ----composition-by-dual-energy-x-ray-absorptiometry (DXA), grip strength, and leg-power.-Serumwas collected at the baseline MrOS visit and the ancillary study but not at Visit 2. The MrOS study protocol was approved by the Institutional Review Board at each of the participating sites and the same protocol was used at all subsequent visits. All participants gave written informed consent.
Serum Albumin
Main Cohort
Participants provided a fasting morning blood-draw during their baseline visit. All blood samples Oregon using a Roche COBAS lntegra 800 automated analyzer (Roche Diagnostics Corp., Indianapolis, IN). The analyzer was calibrated daily in the clinical laboratory and one serum control was included in each assay run. The inter-assay coefficient of variation (CV) was 1.98%. Figure 1 illustrates the eligibility criteria that yielded the main analytic cohort of 5534 participants. Men had to have at least ten aliquots of stored baseline serum for inclusion. There were no material differences between ineligible participants and the main analytic population with regard to age, body composition, muscle strength, or muscle power (Appendix C). A stratified sample of the MrOS cohort had no restriction on the quantity of stored serum aliquots and obtained a baseline serum albumin concentration for 233 of the 461 ineligible participants. The main prospective analysis in this study aimed to quantify the association between a single baseline measure of serum albumin in relation to longitudinal change in measures of muscle mass and muscle function. One concern about this type of study design is the potential for misclassificaiion if there are clinically meaningful changes in serum albumin concentration over
time. An interclass correlation coefficient was calculated using the two serum albumin measures obtained from the sample of men participating in the ancillary study for oral bone loss an I average of two years apart. The interclass correlation coefficient was high (0.98) and provided good evidence for the reliability of serum albumin measures over this time period (Appendix B).
Body Composition
Body composition was measured using dual energy X-ray absorptiometry (DXA) at all study Muscle Strength a n d Power
Grip strength was measured using a JAMAR handheld dynamometer (Sammons Preston, Bolingbrook, Illinois) and two trials were performed for each hand. The average result from all hand measurements was used for the grip strength outcome variable. Leg power was assessed using the Nottingham Power Rig (Bassey & Short, 1990; Bassey et al., 1992) . The maximum result from five trials at each visit was used for the leg power outcome variable. Men who could not perform the grip strength or leg power assessments were classified as "unable" and assigned the first percentile value from the 5-year age category to which they belonged at each study visit (Guralnik et al., 2003) . The muscle function outcome variables were calculated as the absolute change in leg power and grip strength from the MrOS baseline visit to Visit 2 for the main prospective analysis and between the MrOS baseline visit and baseline ancillary study visit for the serum albumin change analysis. Leg power was only assessed at the Portland site during the baseline ancillary study visit.
Participant Characteristics
Self-reported information on demographic factors, medication use, alcohol consumption, smoking status, medical history, and diet was ascertained at MrOS baseline, Visit 2, and the baseline ancillary study visit. Participant height (cm) was measured by research staff using a
Harpenden stadiometer. Weight (kg) was measured on a balance beam or digital scale while wearing shoes and indoor clothing.JRace/ethnicity was categorized into five mutually exclusive
categories: White, Black, Asian, Hispanic, and Other (multiracial persons). Smoking status was categorized into "current", "past", and "never". Physical activity was quantified using the Physical Activity Scale for the Elderly (PASE) (Washburn et al., 1993) and was based on exercise, leisure, household, and occupational activities commonly performed by older adults.
Total caloric intake and protein intake was obtained from a modified food frequency questionnaire developed specifically for MrOS by Block Dietary Data Systems (Boucher et al., 2006) . Protein intake was calculated as a percentage of total caloric intake and was categorized into quintiles. Alcohol consumption was reported as usual number of drinks per day and was categorized into "0 drinks per week", "1-7 drinks per week, and "8+ drinks per week". Medical history was assessed with questions about physician diagnosed myocardial infarction, angina, congestive heart failure, stroke, hypertension, chronic obstructive pulmonary disease, rheumatoid arthritis, osteoarthritis, diabetes, liver disease, renal disease, cancer, and
Parkinson's disease. Medications considered in this analysis were oral corticosteroids, statins, nonsteroidal anti-inflammatory medications (NSAIDS), Cox II inhibitors, aspirin, selective serotonin reuptake inhibitors (SSRls), and thyroid hormone.
Statistical Analysis
For the main prospective analysis quantifying the association of baseline serum albumin with muscle change outcomes, serum albumin concentration was categorized into I-unit increments
and >44 g/L). A scatterplot smoothing parameter was utilized to ensure that this categorization captured the nature of the association between serum albumin concentration and baseline muscle mass, muscle strength, and muscle power.
Baseline characteristics of the main analytic population by serum albumin category were evaluated using one way analysis of variance (ANOVA) for continuous variables and chi-square tests for categorical variables. Baseline characteristics were also assessed with each outcome ---using ANOVA and chi-square tests. Multiple linear regression analyses were performed to -estimate mean differences and their 95% confidence intervals (CI) for measures of muscle mass and muscle function by baseline serum albumin category in a cross-sectional analysis and over time. Two-sided p-values were reported from the F-test and a value of less than 0.05 was considered statistically significant.
Change in the point estimate was used for the selection of confounders with a backward selection process. The absolute change in ASM mass, grip strength, and leg power were the three outcomes assessed and an initial model included baseline serum albumin category, age, study site, and the baseline value of the outcome measure. The gripstrength and leg power absolute change outcome variables were additionally nilodeled with baseline ASM nass and the absolute change in ASM mass to account for differences in body size. All potential confounders associated with both serum albumin and the outcome variable (p<0.25) were added to the initial model (Appendix E). Potential confounding variables that were no longer associated with the outcome in the multivariate model were removed sequentially based on the magnitude of the pvalue. A covariate was excluded from the model if the p-value was greater than or equal to 0.25.
Further, we eliminated variables whose removal from the model resulted in minimal change to the serum albumin least square mean or model R~. Multiple linear regression using generalized linear models was used for each model analysis. Graphical assessment of the adjusted association between serum albumin and each outcome was performed using generalized additive models and a Loess smoothirig parameter.
In the serum albumin change analysis, the change in serum albumin concentration over an average of two years of follow-up was categorized as "marked decrease" (> 3 g/L change), "mild decrease" (1 to 2 g/L change), "stable" (0 g/L change), and "increase" (>O g/L change). The models developed for the primary analysis were additionally adjusted for baseline serum albumin and were used to examine the association between serum albumin change categories
and the simultaneous change in ASM mass, grip strength, and leg power. Multiple linear regression using generalized linear models was performed for each outcome. Stratification by three baseline serum albumin categories (<40 g/L, 40-42 g/L, and 2 43 glL) was conducted to assess possible interaction between baseline serum albumin and change in serum albumin.
Statistical analyses were performed using SAS software version 9.1 (SAS Institute Inc., Cary, NC .
Among the 5534 participants in the main prospective analysis, the mean serum albumin concentration was 42.7 + 2.4 g/L. Most men (98.4%) had a serum albumin concentration in the range considered normal (2 38 g/L) and 460 (8.3%) had a concentration below 40 g/L.
Participants with a serum albumin concentration less than 40 g/L were older (75.4 years and 72.4 years, respectively) and more likely to be African American, nondrinkers, and somewhat less physically active than participants in higher serum albumin categories. They were also more likely to take an oral corticosteroid and less likely to use a statin medication (Table I) .
The cross-sectional analysis demonstrated no association between baseline serum albumin concentration and ASM mass after adjusting for participant age, race, and study site. Table 2 ).
Main Prospective Analysis
Serum albumin concentration at baseline was not associated with the measures of change in muscle mass or muscle function (Table 3) When the change in ASM mass, grip strength, and leg power was modeled with baseline serum albumin concentration in the ancillary study population, the results were similar to findings from the prospective analysis in the main analytic population. The unadjusted and adjusted mean change in ASM mass, grip strength, and leg power over an average of two years of follow-up 1 --_----did not vary according to baseline serum albumin categoy in these participants ( Table 5 ).
In the MrOS cohort, a single measure of serum albumin was not associated with change in muscle mass, muscle strength, or muscle power. The serum albumin change analysis demonstrated no association between serum albumin change over two years of follow-up and the simultaneous change in muscle mass or muscle strength. A statistically significant association was observed between serum albumin change and concurrent change in leg power in a sample of the cohort. However, the magnitude of change was small and the relevance of a change of this magnitude is unknown.
Two longitudinal studies have reported a statistically significant association between serum albumin concentration and subsequent change in measures of muscle mass (Visser et al., 2005) and muscle strength (Schalk et al., 2005) . The current study may appear to contradict past research but there are similarities in the results. In addition, the statistically significant associations.have been small in magnitude. The lowest and highest serum albumin categories The serum albumin change analysis in the current study used a repeated measure of serum albumin in a sample of the cohort to evaluate whetherthe change in serum albumin was more --.
----predictive of the age-related loss of muscle mass and muscle function than a single measure.
The results of this analysis were consistent with the null findings in the main prospective analysis for measures of muscle mass and muscle strength. A statistically significant association between serum albumin change over two years and the simultaneous loss in leg power was observed in this sample of the cohort. However, the difference between men exhibiting a marked change (5 -3 g/L) in serum albumin concentration and men with stable serum albumin over two years was not large and there was considerable overlap in the confidence intervals ( Figure 2 ).
The null results in the current study persisted regardless of the duration of follow-up, use of a single measure versus a change measure of serum albumin concentration, and use of an upper or lower extremity measure of muscle function. Further, these results do not deviate substantially from past findings when evaluating magnitude of change rather than relying on statistical significance. The apparent differences across study populations may have more to do with analysis and interpretation rather than differences in results. For example, the analysis of data from the LASA study population used a one-sided, trend p-value. This methodology can result in smaller p-values than the two-sided F-test that was reported in the present study. When data was analyzed using a one-sided trend p-value rather than the two-sided F-test p-value that is reported in Table 3 , the relation between serum albumin concentration and change in leg power became statistically significant in the current study (p=0.001 vs. p=0.13; data not shown).
In addition, much of the research conducted on this topic has utilized large sample sizes. This can result in associations that are small in magnitude with highly statistically significant p-values.
Albumin is one of the most commonly measured serum proteins and is used to gauge nutritional status-ordisease seyerity in_elderly_patients_(Sullivan,~2001). The-utility-of-this-s-erum-proteiasa marker for the age-related loss of muscle mass and muscle function appears plausible from a biological perspective and promising as a simple tool for early identification of individuals at risk.
However, the limited longitudinal research on this topic questions the use of albumin serum protein for this purpose. Serum albumin can decline in response to physiologic stress (Rothschild et al., 1888) , renal and liver disease (Rothschild et al., 1988; Doweiko & Nompleggi, 1991) , inflammation (Johnson, 1999; Gabay & Kushner, 1999; Sullivan et al., 2007) , and major surgery (Emerson, 1989) . In addition, serum albumin has been reported to decrease by as much as 5 g/L in ambulatory individuals following eight hours of bed rest (Hyltoft et al., 1980) and can vary as much as 11 g/L from the use of different laboratory techniques for measurement (Brackeen, 1989) . It has been argued that the cieciine of serum albumin in response to non-adverse conditions makes it a questionable prognostic indicator in individual Strengths of this study include the availability of a multitude of participant demographic, body composition, serum, dietary, and lifestyle factors. This was the first study to our knowledge that was able to examine the change in serum albumin concentration in relation to measures of both muscle mass and muscle function. In addition, it was the first study that examined upper and lower extremity measures of muscle function in relation to baseline serum albumin concentration. The MrOS study is a cohort of relatively healthy elderly men and a possible limitation is that there was not enough variation in the exposure o i outcome to capture the nature of the association. However, the magnitude of change in the outcomes was similar to other elderly study populations and the LASA study population had a similar distribution of participants with clinically low serum albumin concentration (~3 8 glL). Another limitation is the inability to adjust for inflammation. Results from previous literature have found that adjustment for inflammatory cytokines attenuates the association between serum albumin and change in muscle mass (Visser et al., 2005) and muscle strength (Schalk et al., 2005) . The direction of confounding is unlikely to explain the null findings in the current study but could partially explain the weak association observed between serum albumin change and change in leg power.
Finally, the MrOS study population is a cohort of primarily white men and the results may or may not be generalizable to women or to other racial groups.
Understanding the etiology of the progressive decline of muscle mass and muscle function with age is an important topic in geriatric research. A low concentration of serum albumin has been posited as a potential risk factor due to the biologic plausibility and observation of statistically significant associations that were small in magnitude. The results of this study and the limited body-otresearch on this topic question the utility of albumin serum-protein as a prognostic -- indicator for this process. The investigation of potential risk factors for the age-related loss of muscle mass and muscle function should instead focus on more specific measures of physiologic change such as pro-inflammatory cytokines, growth factor hormones, androgens, and the neuronal and structural changes in skeletal muscle. 
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